Location · Meridian, ID
Clinical trials in Meridian, ID
31 recruiting studies have a site in Meridian, and 10 of them accept healthy volunteers.
31 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Meridian, ID + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingHealthy volunteersPhase 3
A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age
GlaxoSmithKline
- Location
- Meridian, ID + 11 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Meridian, ID + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingHealthy volunteersPhase 3
A Study on the Efficacy of a Vaccine Against Influenza in Adults ≥65 Years of Age
GlaxoSmithKline
- Location
- Meridian, ID + 130 other US sites
- Eligibility basics
- Ages 65+
- RecruitingHealthy volunteersPhase 3
REVEAL Study - Diagnostic Testing for PTSD Using the Senseye Diagnostic Tool
Senseye, Inc.
- Location
- Meridian, ID + 2 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
LEO Pharma
- Location
- Meridian, ID + 21 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Amgen
- Location
- Meridian, ID + 51 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
AbbVie
- Location
- Meridian, ID + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and Pharmacokinetics of Pegloticase Administration Via Subcutaneous and Intravenous Routes Both With Methotrexate in Participants With…
Amgen
- Location
- Meridian, ID + 73 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Meridian, ID + 57 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Location
- Meridian, ID + 51 other US sites
- Eligibility basics
- Ages 12+
- RecruitingPhase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Amgen
- Location
- Meridian, ID + 136 other US sites
- Eligibility basics
- Ages 45–99
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Meridian, ID + 68 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
Uromedica
- Location
- Meridian, ID + 3 other US sites
- Eligibility basics
- Ages 22+ · Women only
- Recruiting
Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure
Boston Scientific Corporation
- Location
- Meridian, ID + 39 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
Amgen
- Location
- Meridian, ID + 69 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
Novo Nordisk A/S
- Location
- Meridian, ID + 26 other US sites
- Eligibility basics
- Ages 8–18
- RecruitingPhase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Pfizer
- Location
- Meridian, ID + 12 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
Eli Lilly and Company
- Location
- Meridian, ID + 120 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
GlaxoSmithKline
- Location
- Meridian, ID + 93 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Amgen
- Location
- Meridian, ID + 117 other US sites
- Eligibility basics
- Ages 18–99
- RecruitingPhase 3
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
AbbVie
- Location
- Meridian, ID + 87 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Apollo Therapeutics Ltd
- Location
- Meridian, ID + 24 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Amgen
- Location
- Meridian, ID + 193 other US sites
- Eligibility basics
- Ages 50–105